Publicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (23)

2022

  1. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  2. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

2021

  1. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma

    Cancers, Vol. 13, Núm. 19

2020

  1. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

    Leukemia, Vol. 34, Núm. 8, pp. 2000-2011

2019

  1. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

    Blood

  2. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

2018

  1. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

    Leukemia, Vol. 32, Núm. 11, pp. 2427-2434

2016

  1. Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma

    Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217

  2. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

    Blood, Vol. 127, Núm. 4, pp. 420-425

  3. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development

    Journal of Hematology and Oncology, Vol. 9, Núm. 1

2015

  1. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631

  2. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

  3. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

    Leukemia

2014

  1. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

    Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773

  2. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

    Haematologica, Vol. 98, Núm. 1, pp. 79-86

  2. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234

  3. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

    Blood, Vol. 122, Núm. 8, pp. 1448-1454

  4. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

2012

  1. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: Antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1879-1888